In a move aimed at combating Shigella infections in low- and middle-income countries, GSK has granted Bharat Biotech International Limited (BBIL) the license to further develop and potentially commercialize its experimental vaccine candidate, altSonflex1-2-3 (1,2). The agreement supports ongoing efforts to address the leading bacterial cause of childhood diarrhea and highlights the growing urgency to tackle antimicrobial resistance associated with enteric pathogens. Source: Biopharm International 12/6/2025